IA
TRDA icon

IFP Advisors’s Entrada Therapeutics TRDA Stock Holding History

IFP Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26K Buy
171
+170
+17,000% +$1.63K ﹤0.01% 4426
2026
Q1 		$13 Buy
+1
New +$11 ﹤0.01% 4950
2025
Q4 		– Sell
-2
Closed -$12 – 5037
2025
Q3 		$12 Buy
+2
New +$12 ﹤0.01% 4779
2025
Q2 		– Sell
-64
Closed -$515 – 4403
2025
Q1 		$579 Sell
64
-23
-26% -$287 ﹤0.01% 3427
2024
Q4 		$1.5K Buy
+87
New +$1.58K ﹤0.01% 3185

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

IFP Advisors's TRDA Position: Q2 2026 in Review

IFP Advisors increased its Entrada Therapeutics (TRDA) stake by 17,000% in Q2 2026, buying an estimated $1.63K and bringing the position to 171 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #4426.

IFP Advisors first reported a position in TRDA in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.5K in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • IFP Advisors held 171 shares of Entrada Therapeutics worth $1.26K as of Q2 2026.
  • IFP Advisors bought 170 Entrada Therapeutics shares in Q2 2026, an estimated $1.63K.
  • Entrada Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4426 holding.
  • IFP Advisors first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • IFP Advisors's Entrada Therapeutics position peaked at $1.5K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.